Abstract
Coxsackievirus B3 (CVB3) causes viral myocarditis, and can ultimately result in dilated cardiomyopathy. There is no vaccine available for clinical use. In the present work, we assessed whether the Sabin3-like mutant of CVB3 could induce a protective immunity against virulent CVB3 Nancy and CVB4 E2 strains in mice by both oral and intraperitoneal (IP) routes. Serum samples, taken from mice inoculated with Sabin3-like, were assayed in vitro for their anti-CVB3 neutralizing activity. CVB3 Sabin3-like was highly attenuated in vivo and was able to induce an anti-CVB3 activity of the serum. However, at 4 days post-CVB3 challenge, significant increased titers of CVB3 neutralizing antibodies were detectable in the sera of immunized mice over the next 6 days. Non-immunized mice challenged with CVB3 Nancy had no anti-CVB3 activity in their sera until 10 days post-infection. CVB3 Nancy induced higher viral titers than did the mutant strain. There was no variation of the neutralizing activity of serum taken from mice immunized with CVB3 Sabin3-like and challenged with CVB4 E2, compared to non-immunized mice. Despite the fact that CVB3 and CVB4 are closely related viruses, virus-neutralizing activity clearly distinguish between these viruses. A variable and limited amount of pancreatic inflammation was seen in some mice 10 days after Sabin3-like inoculation by IP route, whereas there was no evidence of pancreatic damage in mice inoculated by oral route. All immunized mice were protected from myocarditis and pancreatitis at 8 days post-challenge with CVB3 or CVB4 E2. These findings strongly suggest that the mutant strain could be considered a candidate for an attenuated CVB3 vaccine.
Similar content being viewed by others
References
Tam PE (2006) Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 19:133–146
Huber SA, Born W, O’Brien R (2005) Dual functions of murine gammadelta cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vγ1+ and Vγ4+ cells. Microbes Infect 7:537–543
Bailey JM, Tapprich WE (2007) Structure of the 5′ nontranslated region of the coxsackievirus B3 genome: chemical modification and comparative sequence analysis. J Virol 81:650–668
Natarajan P, Johnson JE (1998) Molecular packing in virus crystals: geometry, chemistry, and biology. J Struct Biol 121:295–305
Fohlman J, Pauksen K, Morein B, Bjare U, Ilback NG, Friman G (1993) High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis 88:103–108
Henke A, Jarasch N, Martin U, Wegert J, Wildner A, Zell R, Wutzler P (2008) Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int J Med Microbiol 298:127–134
See DM, Tilles JG (1997) Occurrence of coxsackievirus hepatitis in baby rabbits and protection by a formalin inactivated polyvalent vaccine. Proc Soc Exp Biol Med 216:52–56
Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S (2004) Intranasal delivery of chitosan–DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22:3603–3612
Godney EK, Arizpe HM, Gaunti CJ (1987) –1988). Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol 1:305–314
Ben M’hadheb-Gharbi M, Gharbi J, Paulous S, Brocard M, Komaromva A, Aouni M, Kean KM (2006) Effects of the Sabin-like mutations in domain V of the internal ribosome entry segment on translational efficiency of Coxsackievirus B3. Mol Gen Genomics 276:402–412
Huang ML, Chiang PS, Luo ST, Liou GY, Lee MS (2010) Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71. J Virol Methods 165:42–45
Park JH, Kim DS, Cho YJ, Kim YJ, Jeong SY, Lee SM, Cho SJ, Yun CW, Jo I, Nam JH (2009) Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. Vaccine 27:1974–1983
Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, Huang YC, Shih SR, Chiou ST, Chen PY, Chang HJ, Lin TY (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109:e88
Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, Yang JY (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998–2005. Clin Microbiol Infect 13:782–787
Yoon JW, Austin M, Onodera T, Notkins AL (1979) Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300:1173–1179
World Health Organization (WHO) (1997) Manual for the virological investigation of polio. WHO, Geneva
Dan M, Chantler JK (2005) A genetically engineered attenuated Coxsackievirus B3 strain protects mice against lethal infection. J Virol 79:9285–9295
Dunn JJ, Bradrick SS, Chapman NM, Tracy SM, Romero JR (2003) The stem loop II within the 5′ nontranslated region of clinical Coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model. J Infect Dis 187:1552–1561
Kim JY, Jeon ES, Lim BK, Kim SM, Chung SK, Kim JM (2005) Immunogenicity of a DNA vaccine for Coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 23:1672–1679
Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497
Tu Z, Chapman MN, Hufnagel G, Tracy S, Romero JR, Barry WH, Zhao L, Currey K, Shapiro B (1995) The cardiovirulent phenotype of Coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region. J Virol 69:4607–4618
Ben M’hadheb-Gharbi M, Kean KM, Gharbi J (2009) Molecular analysis of the role of IRES stem-loop V in replicative capacities and translation efficiencies of Coxsackievirus B3 mutants. Mol Biol Rep 36:255–262
Le SY, Siddiqui A, Maizel JV (1996) A commun structural core in the internal ribosome entry sites of picornavirus, hepatitis C virus and pestivirus. Virus Genes 12:135–147
Rinehart LO, Gomez RM, Root RP (1997) Molecular determinants for virulence in coxsackievirus B1 infection. J Virol 71:3986–3991
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jrad-Battikh, N., Souii, A., oueslati, L. et al. Neutralizing Activity Induced by the Attenuated Coxsackievirus B3 Sabin3-like Strain Against CVB3 Infection. Curr Microbiol 68, 503–509 (2014). https://doi.org/10.1007/s00284-013-0498-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00284-013-0498-z